These findings suggest that the concurrent treatment with not only an antiandrogen, which has been widely used in patients with, for example, prostate cancer, but also a GABBR2 inhibitor, may considerably enhance the efficacy of CDDP-based chemotherapy, particularly in patients with AR-positive/GABBR2-positive bladder cancer. Here, AR is linked to urinary bladder cancer.